Ensol Bio Science Targets KOSDAQ Transfer on FDA Fast-Track and Obesity Licensing
KONEX-listed Ensol Bio Science will pursue a first-half 2026 KOSDAQ transfer listing, anchored by FDA accelerated-approval talks for disc-drug P2K, H1K obesity out-licensing and E1K Phase 3 dosing of 358 patients.
TAG E-6700 · 764 words on the filing

Summary of findings
- Ensol Bio Science targets KOSDAQ transfer listing in H1 2026 via technology-special listing evaluation.
- P2K accelerated-approval coordination meeting with Spine BioPharma set for December 1–2 in New York; FDA pathway talks planned through 2027.
- E1K Phase 3 dosing of 358 patients across 20 Korean hospitals, including Samsung Medical Center, starts in April 2026.
- 40 billion won (about $3.0 million) advance payment received from Leaders Cosmetics under E1K distribution deal.
- H1K oral obesity drug suppressed GLP-1 rebound weight gain in non-clinical tests; licensing talks with a global pharma resumed.
Ensol Bio Science, a KONEX-listed South Korean biotech, has set a KOSDAQ transfer listing for the first half of next year, staked on three catalysts: FDA accelerated-approval talks for its degenerative disc disease drug P2K, due diligence with a global pharmaceutical company on an oral obesity treatment out-license, and animal-model efficacy data for an anticancer radiopharmaceutical.
The company laid out the pipeline status and listing roadmap at its second-half investor relations event on the 18th at the Korea Exchange in Yeouido, Seoul. It plans to enter the technology evaluation required for a KOSDAQ technology-special listing once those achievements become visible.
What does the December New York meeting change?
The heaviest-weighted asset is P2K (PENIEL 2000). On December 1–2, Ensol Bio will meet at its U.S. partner Spine BioPharma's New York headquarters, with top executives of both companies attending. The agenda covers:
- FDA accelerated-approval pathway and timeline coordination
- Governance for sharing clinical data
- A joint response in U.S. capital markets
- Nasdaq listing strategy
Based on that meeting, the company plans to negotiate the regulatory pathway with the FDA through 2027 to secure accelerated approval. Whether the pathway applies at all — and when — rests on the outcome of those FDA talks.
E1K Phase 3 moves to 358-patient dosing in April
For E1K (ENGEDI 1000), a knee osteoarthritis treatment, the company has completed dosing of six subjects in the safety-assessment portion of its South Korean Phase 3 trial. Twenty major university hospitals, including Samsung Medical Center, have confirmed participation. Dosing of 358 patients begins in April next year. The goal is a disease-modifying osteoarthritis drug that induces cartilage regeneration and suppresses disease progression rather than merely relieving pain. Technology-transfer negotiations run in parallel by region, covering China, India and the United States.
H1K obesity data revive licensing talks
H1K (HADASSAH 1000), an oral obesity treatment positioned as the next growth engine, drew market attention with non-clinical results. The molecule carries a pH-selective dual-target mechanism: it activates IGF-1R, which regulates metabolic signals, in the acidic gastrointestinal environment (pH 2–5), and inhibits CD28, an inflammation-inducing factor, in the neutral liver environment (around pH 7.4). In non-clinical efficacy tests, it significantly suppressed the weight rebound — the yo-yo effect — seen after stopping co-administration with a GLP-1-class obesity drug. Ensol Bio has assembled the data package a global pharmaceutical company requested and resumed technology-transfer discussions.
Follow-on pipeline and the balance sheet
M1K (MORIAH 1000), an Alzheimer's treatment, restored cognitive function to normal levels in a disease animal model; the company will submit an Investigational New Drug application for a Phase 1 trial in the first half of next year. The lineup also includes combination anticancer drugs C1K, C2K and C3K, targeting triple-negative breast cancer, non-small cell lung cancer and colorectal cancer, plus D1K-PRC, a peptide-based anticancer radiopharmaceutical developed jointly with Saehan Industry.
Financial restructuring moved in parallel:
- Capital soundness improved through a large-scale common-share investment by largest shareholder and CEO Hyung In-woo, a common-share investment by Capstone Partners, and conversion of convertible bonds into common shares.
- The company secured R&D liquidity by receiving in full a 40 billion won (approximately $3.0 million) advance payment under an exclusive South Korean distribution agreement for E1K with Leaders Cosmetics (016100).
- It reselected Shinhan Securities as lead underwriter, completed corporate due diligence and rewrote its technology business plan around its biomimetic "fresh thread" (SSR™) peptide platform.
The decision not to rush the listing reflects subdued biotech investment sentiment: management chose to build earnings and clinical results first. Research on E1K and C1K appeared in an authoritative osteoarthritis journal and an international biopolymer journal, respectively; the M1K paper is under review at an international academic journal.
Both the FDA accelerated-approval route and the H1K technology transfer depend on negotiations with counterparties, so whether the first- and second-quarter catalysts convert into signed outcomes will decide the listing.
CEO Kim Hae-jin said: "We are resolving financial uncertainty and accumulating tangible results in the clinical development and global partnering of our key pipelines." He added: "We will maximize shareholder value by entering the KOSDAQ technology evaluation at the optimal time, in line with our core R&D and commercialization achievements in the first half of next year."
A KONEX biotech entering KOSDAQ on two pillars — a large-scale technology transfer and global clinical trials — is rare; the counterparty negotiations, not the calendar, now set the pace.
via FDA industry wire (Google News) (Source)
More from Olivia Hart
Show full bio
Senior reporter covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.
13 articles
Linked filings
- K-5457
- P-6323
- C-9698
- C-4460
- C-6506